Aurelie is a member of DLA Piper's White-Collar, Investigations and Government Enforcement practice group. Her practice focuses on government and internal investigations and white-collar criminal matters, with a concentration on the Foreign Corrupt Practices Act (FCPA), US sanctions and export controls and the False Claims Act (FCA).
She has conducted numerous cross-border corruption and economic sanctions investigations in Africa, Asia, Eastern Europe, the Middle East and South America and successfully defended her clients in related government investigations and regulatory enforcement actions, including whistleblower actions. As a native French speaker barred in Paris, Aurelie focuses on matters involving French speaking jurisdiction, particularly North Africa. She has also experience advising clients in matters implicating the FCA and the Anti-Kickback Statute. Her clients include public and private companies in the life sciences, technology, financial services, consumer goods and industrial sectors.
Aurelie also regularly counsels on regulatory compliance, including risks and controls relating to international corruption and sanctions, among other things.
Aurelie has represented:
- A global life sciences company in connection with joint DOJ and SEC bribery investigations relating to business activities in Latam.
- A U.S.-based fintech company in connection with joint DOJ and FTC investigations of Payroll Protection Plan (PPP) lending practices.
- A U.S.-based medical device company in connection with a DOJ investigation into alleged violations of the FCA in connection with the submission of claims for reimbursement to various Federal Healthcare Programs.
- A global public technology company in connection with a DOJ/SEC investigation of alleged bribery violations obtaining a DOJ declination letter.
- A global medical device and welding manufacturer in an internal investigation and self-disclosure to OFAC and BIS of potential violations of the Ukraine/Russia sanctions program and resulting in a Cautionary Letter and Warning Letter, respectively.
- A global life sciences company in connection with DOJ/SEC investigations of alleged FCPA violations in Asia resulting in no enforcement action.
Aurelie has advised:
- Several global pharmaceutical companies in connection with dozens of internal investigations involving the companies' operations in Africa, the Middle-East, Asia, Eastern Europe and South America regarding anti-corruption concerns around the use of the companies' speaker program, Advisory Board Meetings, corporate sponsorships and educational grants as means to provide potentially improper benefits to Key Opinion Leaders.
- A global technology company in connection with an internal investigation into potential violations of the Iran sanctions program.
- A global consumer goods company in connection with an internal investigation into potential violations of the Iran sanctions program.
- A French biotechnology company on potential FCA and AKS risk exposure regarding the operations of their U.S. subsidiary.
- LL.M., University of California at Los Angeles School of Law
- J.D., University of Paris II, Panthéon-Assas, France
magna cum laude
My latest insights
What 2022 can tell us about corporate criminal enforcement in 2023
13 February 2023 .7 minute read
White House issues first ever Strategy on Countering Corruption: Key highlights
6 December 2021 .4 minute read